David Steinberg
Acting Chief Executive Officer, Board Member

Mr. Steinberg is a Partner at PureTech Ventures, where he has been on the founding teams of Enlight Biosciences and Endra Inc. as founding CEO and board member. Previously, he served as Chief Business Officer of portfolio company Follica, Inc., and VP of Operations for portfolio company Satori Pharmaceuticals. Prior to joining PureTech, he was a strategy consultant with the Boston Consulting Group and Vertex Partners, focusing on R&D and product strategy and strategic alliances for Fortune 500 pharmaceutical and biotechnology firms. Mr. Steinberg also worked as a research associate in Procter and Gamble Pharmaceuticals' R&D organization. Mr. Steinberg received his BA in Biology with distinction from Cornell University and graduated with high honors from the University of Chicago Graduate School of Business with an MBA in strategy and finance.

Michael Thornton
Chief Operating Officer

Prior to joining Endra in 2007, Michael Thornton was a founder and President of Enhanced Vision Systems Corp. (EVS), a developer and supplier of medical imaging equipment to the pharmaceutical, biotech, and academic sectors. In 2002, EVS was acquired by General Electric and was integrated into the Functional and Molecular Imaging business unit of GE Medical Systems (now GE Healthcare).Following the acquisition of EVS by GE Medical Systems, Mr. Thornton held a number of positions at GE Healthcare, including Sales Manager, Global Product Manager, and Site Leader. He was a member of the leadership team that expanded the preclinical imaging business to include: CT (computed tomography), optical, and PET (positron emission tomography) imaging technologies, with global market reach. He is also a founder of Volumetrics Medical Corp. a developer and manufacturer of quality assurance devices for diagnostic imaging. Prior to founding EVS, Mr. Thornton developed medical imaging related technologies at the Robarts Research Institute (London, ON) for which he obtained an MSc in Electrical Engineering from the University of Western Ontario. Mr. Thornton also holds a BASc in Electrical Engineering from the University of Toronto, and is a member of the American Association of Physicists in Medicine.

Dr. Paul Picot
Director, Technology & Product Development

Prior to joining Endra, Dr. Picot was Chief Scientist and Global Product Manager for Computed Tomography with GE Healthcare Pre-Clinical Imaging. Previously, Dr. Picot managed a MRI research facility and was assistant professor of Medical Biophysics at the University of Western Ontario. Prior to that, he was Assistant Professor of Kinesiology and managed the Cerebral Blood Flow Research Laboratory, UWO, developing instrumentation to study brain physiology. He was a principal developer of 3-D Doppler ultrasound, later commercialized by Life Imaging Systems. He has also consulted for industry in medical device design and certification, including Advanced Technology Laboratories and Philips Medical Systems. Dr. Picot holds a double B.Sc. in Physics and Biology from the University of New Brunswick, trained at Robarts Research Institute, and earned a Ph.D. in Medical Biophysics from the University of Western Ontario. He has more than 20 years of experience in medical imaging and instrument design.

Dr. Timothy Morgan
Product Manager

Prior to joining Endra in 2008, Dr. Morgan was the SPECT Global Product Manager in Pre-Clinical Imaging at GE Healthcare. In this role, he provided leadership during commercialization of GE Healthcare's first small animal single photon emission computed tomography (SPECT) scanner. He also held positions of Applications Specialist and Advanced Applications Specialist at GE Healthcare, guiding the development of new pre-clinical applications for micro-computed tomography (microCT) imaging. Dr. Morgan completed his M.S. and Ph.D. in Mechanical Engineering at Cornell University where he developed models of cancellous bone adaptation using microCT imaging and finite element analysis to examine the skeletal response to mechanical forces. Timothy holds a B.S. in Mechanical Engineering from Louisiana State University.

Dr. Katherine Ferrara
Member, Scientific Advisory Board

Katherine Ferrara is a professor of Biomedical Engineering at UC Davis. She has held appointments at the Riverside Research Institute, Cornell Medical School and the University of Virginia before her recruitment to UC Davis to found the Department of Biomedical Engineering and to serve as the chair for six years. She is a fellow of the Acoustical Society of America, the American Institute of Medical and Biological Engineering and the Biomedical Engineering Society. She is a member of the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering and the advisory councils of the Society for Molecular Imaging, the International Society for Therapeutic Ultrasound and the Whitaker Fellows program. From 1983-8, she worked for General Electric Medical Systems contributing to early prototypes of magnetic resonance and ultrasound imaging systems. Her research interests span medical imaging and drug delivery. She received her Ph.D. in Electrical Engineering from UC Davis in 1989.

Dr. Sanjiv Sam Gambhir
Board Member

Dr. Sanjiv Sam Gambhir is a Professor of Radiology and Bioengineering at Stanford University. He is the Head of Nuclear Medicine and Director of the Molecular Imaging Program at Stanford (MIPS) (http://mips.stanford.edu) and a member of the Bio-X program at Stanford University. He trained at the University of California Los Angeles (UCLA) in the Medical Scientist Training Program where he obtained both his M.D., and Ph.D. Dr. Gambhir has a translational science laboratory that focuses on multimodality molecular imaging including new probe development for positron emission tomography (PET) and optical imaging. His laboratory has developed methods to image gene expression in living subjects including humans. These imaging strategies have been translated into clinical trails for human gene/cell therapies. He has developed several small animal imaging strategies for studying basic cell/molecular biological events including imaging protein-protein interactions, intramolecular folding, and cell trafficking. Dr. Gambhir also has extensive experience with clinical FDG PET and developed many of the original management algorithms for cancer patients including cost-effectiveness models that led to FDG reimbursement by Medicare. He has received several awards including the Taplin Award (2002), Holst Medal (2003), the Academy of Molecular Imaging Basic Scientist Award (2004), the Society of Molecular Imaging Achievement Award (2004), the Distinguished Clinical Scientist Award from the Doris Duke Charitable Foundation (2004), the Hounsfield Medal for Imperial College London (2006), the Aebersold Award from Society of Nuclear Medicine (2006), and the Tesla Medal from the British Radiological Society (2008). He is a fellow of the American Institute for Medical and Biological Engineers (AIMBE) and a fellow of the American Society of Clinical Investigation (ASCI). He is one of 35 members of the National Cancer Institute (NCI) Scientific Advisory Board and also co-hosted the Nobel Symposium on Molecular Imaging in Stockholm in 2007. He serves as an advisor to over 10 imaging/biotechnology companies and is Associate Editor of several journals including the Journal of Nuclear Medicine and the journal Radiology.

David Steinberg
Board Member

Mr. Steinberg is a Partner at PureTech Ventures, where he has been on the founding teams of Enlight Biosciences and Endra Inc. as founding CEO and board member. Previously, he served as Chief Business Officer of portfolio company Follica, Inc., and VP of Operations for portfolio company Satori Pharmaceuticals. Prior to joining PureTech, he was a strategy consultant with the Boston Consulting Group and Vertex Partners, focusing on R&D and product strategy and strategic alliances for Fortune 500 pharmaceutical and biotechnology firms. Mr. Steinberg also worked as a research associate in Procter and Gamble Pharmaceuticals' R&D organization. Mr. Steinberg received his BA in Biology with distinction from Cornell University and graduated with high honors from the University of Chicago Graduate School of Business with an MBA in strategy and finance.

Alexander Tokman
Board Member

Alexander Tokman, has served as President, Chief Executive Officer and a director of Microvision since January 2006. Previously Mr. Tokman completed a successful 10+ year tenure as an executive with GE Healthcare, where he led several global businesses, most recently as a General Manager of its Global Molecular Imaging and Radiopharmacy multi-technology business unit from 2003 to 2005. Between 1995 and 2003, Mr. Tokman served in various leadership roles at GE where he led the definition and successful commercialization of several product segments including PET/CT, which generated $500M+ of revenue within the first three years of launch. Mr. Tokman is a certified Six Sigma and Design for Six Sigma (DFSS) Black Belt and Master Black Belt and as one of GE's Six Sigma pioneers, he drove the quality culture change across GE Healthcare in the late 1990's. From 1989 to 1995 Mr. Tokman served as development programs lead and a head of I&RD at Tracor Applied Sciences. Mr. Tokman has both a M.S. and B.S. in Electrical Engineering from the University of Massachusetts, Dartmouth.

Dr. Lihong Wang
Chairman, Scientific Advisory Board

Dr. Lihong Wang currently holds the Gene K. Beare Distinguished Professorship at Washington University in St. Louis, and is widely recognized as a world leader and pioneer in the field of photoacoustic imaging. He has authored one of the first textbooks on biomedical optics, and is editor for the first comprehensive book on biomedical photoacoustic tomography. He has published 170 peer-reviewed journal articles and delivered 198 keynote, plenary, and invited talks. He is a fellow of the AIMBE, OSA, IEEE, and SPIE. He serves as an equal co-chair for the annual conference on Photons plus Ultrasound, the 2010 Gordon Conference on Lasers in Medicine and Biology, and the 2010 OSA Topical Meeting on Biomedical Optics. He also serves as an equal co-chair for the International Biomedical Optics Society. He is a chartered member on an NIH study section. He has served as Principal Investigator on 12 NIH grants, totaling >$21M. His laboratory invented or discovered frequency-swept ultrasound-modulated optical tomography, dark-field confocal photoacoustic microscopy (PAM), optical-resolution PAM, photoacoustic Doppler sensing, photoacoustic reporter gene imaging, focused scanning microwave-induced thermoacoustic tomography, Mueller-matrix optical coherence tomography, optical coherence computed tomography, and oblique-incidence reflectometry. His Monte Carlo model of photon transport in scattering media has been used worldwide.

Yishai Zohar
Board Member

Mr. Zohar is the CEO and Co-founder of Gelesis Inc., developing innovative technologies to treat obesity and other major, unmet medical needs. Previously Mr. Zohar was a Co-Founder and Partner of PureTech Ventures, a Boston-based venture group focused on the translation of academic breakthroughs into commercially viable companies. In his role at PureTech he co-founded and ran several innovative companies, including Gelesis. Prior to co-founding PureTech, Mr. Zohar co-founded and was the CEO of Zeta Ltd, a market leader in the Israeli consumer/edible goods market. He has a degree in marketing and finance from Tel Aviv and was a pilot (Captain) in the Israeli Air Force.